Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms
- 7 January 2016
- journal article
- research article
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 39 (5) , 567-576
Abstract
Purpose To describe the clinical and biochemical profile of patients with primary hyperparathyroidism (PHPT) of the Swiss Hyperparathyroidism Cohort, with a focus on neurobehavioral and cognitive symptoms and on their changes in response to parathyroidectomy. Methods From June 2007 to September 2012, 332 patients were enrolled in the Swiss PHPT Cohort Study, a nationwide prospective and non-interventional project collecting clinical, biochemical, and outcome data in newly diagnosed patients. Neuro-behavioral and cognitive status were evaluated annually using the Mini-Mental State Examination, the Hospital Anxiety and Depression Scale, and the Clock Drawing tests. Follow-up data were recorded every 6 months. Patients with parathyroidectomy had one follow-up visit 3–6 months’ postoperatively. Results Symptomatic PHPT was present in 43 % of patients. Among asymptomatic patients, 69 % (131/189) had at least one of the US National Institutes for Health criteria for surgery, leaving thus a small number of patients with cognitive dysfunction or neuropsychological symptoms, but without any other indication for surgery. At baseline, a large proportion showed elevated depression and anxiety scores and cognitive dysfunction, but with no association between biochemical manifestations of the disease and test scores. In the 153 (46 %) patients who underwent parathyroidectomy, we observed an improvement in the Mini-Mental State Examination (P = 0.01), anxiety (P = 0.05) and depression (P = 0.05) scores. Conclusion PHPT patients often present elevated depression and anxiety scores and cognitive dysfunction, but rarely as isolated manifestations. These alterations may be relieved upon treatment by parathyroidectomy.Keywords
Funding Information
- Amgen (US)
This publication has 50 references indexed in Scilit:
- Pharmacological Treatment of Obesity in Patients with Polycystic Ovary SyndromeJournal of Obesity, 2010
- Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with “asymptomatic” primary hyperparathyroidismSurgery, 2009
- Neuropsychological Features in Primary Hyperparathyroidism: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International WorkshopThe Journal of Clinical Endocrinology & Metabolism, 2009
- Medical Observation, Compared with Parathyroidectomy, for Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized TrialThe Journal of Clinical Endocrinology & Metabolism, 2007
- Parathyroidectomy improves neurocognitive deficits in patients with primary hyperparathyroidismSurgery, 2005
- A controlled, prospective study of neuropsychological outcomes post parathyroidectomy in primary hyperparathyroid patientsClinical Endocrinology, 2004
- Clinical Manifestations of Primary Hyperparathyroidism Before and After Parathyroidectomy A Case-Control StudyAnnals of Surgery, 1995
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983
- Malignant neoplasms and parathyroid adenomaCancer, 1971